Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Survival Based on Genetic and Clinical Features in Parkinson’s Disease
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
087

To assess survival and correlation with MAPT and APOE gene variants and clinical factors in a large cohort of Parkinson disease (PD) patients.
Several large cohort studies have assessed genetic risk associated with survival in PD. MAPT and APOE have been variably linked to risk of dementia in PD, but have not been examined in association with survival.

We utilized the Molecular Epidemiology of PD Mayo Clinic database that enrolled 1103 PD patients from 1996-2007 and included genomic DNA collection. Survival time was calculated by review of medical records, public archives, patient letter, or telephone contact. The primary outcome was time to death, stratified by sex and age-at-onset. Clinical data included PD duration, family history, cognition, mood, and motor symptoms. A secondary analysis evaluated the association of MAPT and APOE genotypes with survival, using Cox proportional hazard regression.
There was follow-up survival data on 1048 PD patients, 692 (66%) male, with mean age-of-onset 63.0 years (males 63.1vs. females 63.0, p=0.92). Of these, 892 (85%) had died. Median survival was 15.4 years after diagnosis (15.0 males, 16.5 females, p=0.004). Deceased males (n=596) and females (n=304) had older mean age-of-onset compared to their alive counterparts (p<0.001). When stratified by sex, hallucinations (HR 1.4, p=0.02) and depression (HR 1.2, p=0.03) were associated with shortened survival in females and males, respectively. There was no correlation between MAPT and APOE variants and survival (n=923).

Female sex and younger age-of-onset were associated with longer survival in PD. Presence of hallucinations in females and depression in males increased mortality. There was no association of MAPT and APOE gene variants with survival.
Authors/Disclosures
Sushma Kola, MD
PRESENTER 		Dr. Kola has nothing to disclose.
No disclosure on file
No disclosure on file
Owen A. Ross, PhD (Mayo Clinic Jacksonville) Dr. Ross has nothing to disclose.
Demetrius M. Maraganore, MD, FÂ鶹´«Ã½Ó³»­ (Tulane University School of Medicine) Dr. Maraganore has nothing to disclose.
Anhar Hassan, MBBCH, FRACP, FRCPI, FÂ鶹´«Ã½Ó³»­ (Beaumont Hospital) The institution of Dr. Hassan has received research support from Intrabio . Dr. Hassan has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with Korean Movement Disorders Society.